Health Condition 1: J308- Other allergic rhinitis
Conditions
Interventions
Intervention1: Intranasal Azelastine hydrochloride spray combined with Fluticasone furoate Intranasal spray: Fluticasone Furoate intranasal spray 27.5 g combined with Azelastine hydrochloride nasal s
Sponsors
Dr Sumitha A Self
Eligibility
Inclusion criteria
Inclusion criteria: Patients diagnosed with Moderate to severe allergic rhinitis. Patients willing to give consent for participating in the study.
Exclusion criteria
Exclusion criteria: Patients with asthma (by clinical findings and spirometric method) Patients with Chronic Obstructive Pulmonary disease (COPD). Patients with nasal bleeding,deviated nasal septum,obstructing nasal polyps,Paranasal sinuses (by ENT examination) Tuberculosis patients. Diabetic and Hypertensive patients. Smokers. Patients who received systemic or topical corticosteroids,Intranasal antihistamines, herbal drugs within the previous month of enrolment. Previous history of hypersensitivity to steroids,antihistamines. Patients with history of atopic dermatitis,tropical eosinophilia syndrome. Patients who received oral antihistamines/other drugs for upper respiratory tract infection within the previous month of enrolment. Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the changes (reduction in scores) in total nasal symptom score (TNSS). To evaluate the percentage of reduction in FeNO (Fractional exhaled nitric oxide) levels. To assess the changes in Serum IgE levels.Timepoint: Baseline,1 st month of treatment and 3rd month of followup. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To assess the changes in Absolute eosinophil count. 2.Adverse drug reactions recorded (history) during the study period.Timepoint: Basline,1 st month of treatment and 3 rd month of followup. | — |
Countries
India
Contacts
Public ContactDr C S Brethis
ACS Medical college and Hospital,Dr MGR Educational and Research Institute
Outcome results
None listed